(Reuters) – Gilead Sciences said on Saturday that it entered into a partnership with Denmark’s LEO Pharma to develop programs to treat patients with inflammatory diseases. The Danish company will be eligible to receive up to $1.7 billion in payments which include an upfront payment of $250 million from Gilead. In return, Gilead will have global rights to develop, manufacture, and commercialize the small molecule oral STAT6 (signal transducer and…

WTVB

Gilead, LEO Pharma partner to develop programs for inflammatory diseases

All Sides

Midwest Communications

Media Bias/Fact Check

Seeking Alpha

United States

Gilead in pact for anti-inflammatory drugs in a deal worth up to $1.7B

Leo Pharma signs huge deal: Value could grow to more than DKK 12 billion.Danish Leo Pharma has signed an agreement with US giant Gilead. This is a very significant agreement, as

Leo Pharma indgår kæmpeaftale: Værdi kan vokse til mere end 12 mia. kr.Danske Leo Pharma har indgået en aftale med den amerikanske gigant Gilead.  Der er tale om en ganske markant aftale, som udl

Leo Pharma indgår kæmpeaftale: Værdi kan vokse til mere end 12 mia. kr.

borsen.dk

Leo Pharma signs huge deal: Value could grow to more than DKK 12 billion

The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.

BizToc

Gilead, Leo Pharma Form Pact Focused on Inflammatory Diseases

Gilead Sciences is acquiring LEO Pharma’s oral small molecule inhibitors of STAT6, a protein key to two validated inflammation pathways. Other STAT6 drug developers include Kymera Therapeutics and Sanofi-partnered Recludix Pharma, which is presenting this week during the J.P. Morgan Healthcare Conference. The post Gilead’s New $250M Drug R&D Pact Adds Contenders in the Hunt for Hot Inflammation Target appeared first on MedCity News.

MedCity News

Gilead’s New $250M Drug R&D Pact Adds Contenders in the Hunt for Hot Inflammation Target

— Strategic Partnership Strengthens Gilead’s Inflammation Research Portfolio with the Addition of LEO Pharma’s Preclinical Oral STAT6 Program, Including Targeted Protein Degraders — — Gilead Will Have Exclusive Global Rights to the STAT6 Program, and LEO Pharma Will Have the Option to Co-Commercialize for Dermatology Indications Outside the U.S. — — LEO Pharma to Maintain Global Rights to Topical Formulations of the STAT6 Program in Dermatology …

pipelinereview

Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases - Pipelinereview

regionalmedianews.com

Gilead, LEO Pharma partner to develop programs for inflammatory diseases - Regional Media News

Sundry Photography Gilead Sciences ( NASDAQ: GILD) and Danish pharmaceutical business LEO Pharma on Saturday revealed an arrangement worth approximately $1.7 B to collectively establish and advertise LEO’s anti-inflammatory drugs. As part of the offer, Gilead ( NASDAQ: GILD) will purchase LEO Pharma’s anti-inflammatory representatives, which Source: Business Insider. The post Gilead inks deal for anti-inflammatory drugs (GILD:NASDAQ) appeared fi…

The New York Ledger

Gilead inks deal for anti-inflammatory drugs (GILD:NASDAQ)

US drugmaker Gilead Sciences has partnered with Danish company LEO Pharma to develop programs aimed at treating patients with inflammatory diseases, Reuters reports.

Producătorul american de medicamente Gilead Sciences a încheiat un parteneriat cu compania daneză LEO Pharma pentru a dezvolta programe destinate tratării pacienţilor cu boli inflamatorii, transmite Reuters.

Gilead, LEO Pharma partner to develop programs for inflammatory diseases

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics